Drugs for Gastrointestinal Diseases Practice Questions

Q: Which drug is used to manage Cisplatin-induced nausea and vomiting occurring within 24 hours?

Ondansetron. ### Explanation **Correct Answer: C. Ondansetron** **Mechanism and Rationale:** Cisplatin is a highly emetogenic chemotherapy agent that triggers vomiting via two phases: **Acute** (within 24 hours) and **Delayed** (after 24 hours). * **Acute phase:** Mediated primarily by the release of **Serotonin (5-HT)** from enterochromaffin cells in the GI tract, which stimulates 5-HT3 receptors on vagal afferents. * **Ondansetron** is a selective **5-HT3 receptor antagonist** and is the first-line drug of choice for preventing acute chemotherapy-induced nausea and vomiting (CINV). **Analysis of Incorrect Options:** * **A & B (Aprepitant/Fosaprepitant):** These are **NK1 receptor antagonists**. While they are used in Cisplatin regimens, their primary role is in managing the **delayed phase** of vomiting (mediated by Substance P). They are usually combined with 5-HT3 antagonists and dexamethasone for highly emetogenic protocols. * **D (Promethazine):** This is a first-generation H1-antihistamine with dopamine-blocking properties. It is used for motion sickness or mild nausea but is **ineffective** against the potent emetogenic stimulus of Cisplatin. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of Choice (DOC):** 5-HT3 antagonists (Ondansetron/Palonosetron) are the DOC for acute CINV and post-operative nausea/vomiting (PONV). 2. **Palonosetron:** A newer 5-HT3 antagonist with a longer half-life; it is the only drug in its class effective for *both* acute and delayed phases. 3. **Side Effects:** The most common side effects of Ondansetron are **headache** and **constipation**. It can also cause **QT interval prolongation**. 4. **Triple Therapy:** For highly emetogenic drugs like Cisplatin, the standard of care is a combination of a 5-HT3 antagonist + Dexamethasone + NK1 antagonist.

Q: A 27-year-old woman occasionally uses calcium carbonate for 'heartburn' symptoms after a large meal. What is the mechanism of action of the prescribed medication for an acid-peptic disorder?

Neutralizes gastric acid. **Explanation:** The patient is using **Calcium carbonate**, which belongs to the class of **Antacids**. These are weak bases that react with gastric hydrochloric acid (HCl) to form salt and water. **1. Why Option A is Correct:** The primary mechanism of antacids is the **neutralization of gastric acid**. By reacting with HCl, they increase the gastric pH. This reduction in acidity not only provides immediate relief from "heartburn" but also decreases the activity of pepsin (which is inactive above pH 4), thereby protecting the esophageal and gastric mucosa from acid-pepsin digestion. **2. Why the Other Options are Incorrect:** * **Option B (Binds to cysteine):** This refers to the mechanism of **Proton Pump Inhibitors (PPIs)** like Omeprazole. PPIs form a covalent disulfide bond with cysteine residues on the $H^+/K^+$-ATPase pump. * **Option C (Inhibits gastrin release):** While some drugs like Octreotide can inhibit gastrin, standard acid-peptic medications do not primarily work this way. Antacids may actually cause "acid rebound" by stimulating gastrin release due to the sudden rise in pH. * **Option D (Irreversible H1-receptor blockade):** This is incorrect on two counts. Drugs for acid-peptic disease target **H2-receptors** (e.g., Ranitidine), and this blockade is typically **reversible**. H1-blockers are used for allergies. **High-Yield Clinical Pearls for NEET-PG:** * **Milk-Alkali Syndrome:** Excessive intake of Calcium carbonate with calcium-rich foods can lead to hypercalcemia, metabolic alkalosis, and renal failure. * **Drug Interactions:** Antacids can adsorb or change the ionization of other drugs (e.g., Tetracyclines, Iron, Fluoroquinolones), reducing their absorption. Always maintain a 2-hour gap. * **Systemic vs. Non-systemic:** Sodium bicarbonate is systemic (absorbable), while Aluminum/Magnesium hydroxides and Calcium carbonate are largely non-systemic.

Q: Omeprazole effects are due to:

Proton pump inhibitor. **Explanation:** **Omeprazole** is the prototype of the **Proton Pump Inhibitors (PPIs)**. It works by irreversibly inhibiting the **H+/K+ ATPase enzyme** (the proton pump) located on the apical membrane of gastric parietal cells. This enzyme represents the "final common pathway" of gastric acid secretion; by blocking it, PPIs effectively suppress acid production regardless of the stimulus (histamine, gastrin, or acetylcholine). **Analysis of Options:** * **Option A (Prostaglandin analogue):** This refers to drugs like **Misoprostol** (PGE1 analogue), which increase mucosal bicarbonate/mucus secretion and decrease acid production. * **Option B (H2 antihistamines):** These are drugs like **Ranitidine and Famotidine**. They competitively inhibit H2 receptors on parietal cells, but are less potent than PPIs because they do not block the gastrin or vagal pathways. * **Option D (Ulcer protective mechanism):** This refers to agents like **Sucralfate or Colloidal Bismuth Subcitrate**, which form a physical barrier over the ulcer base to prevent acid/pepsin damage, rather than inhibiting acid secretion itself. **Clinical Pearls for NEET-PG:** 1. **Mechanism:** Omeprazole is a **prodrug**. It is activated in the acidic environment of the canaliculi to form a sulfenamide derivative that covalently binds to the pump. 2. **Administration:** It is administered as **enteric-coated granules** to prevent premature activation by gastric acid before reaching the systemic circulation. 3. **Timing:** Should be taken **30–60 minutes before a meal** (usually breakfast) for maximum efficacy, as the number of pumps is highest after a fast. 4. **Side Effects:** Long-term use is associated with **Hypomagnesemia**, Vitamin B12 deficiency, and increased risk of *C. difficile* infections and osteoporotic fractures.

Q: Which of the following medications is used to treat opioid-induced constipation?

Alvimopan. **Explanation:** **1. Why Alvimopan is Correct:** Opioid-induced constipation (OIC) occurs because opioids stimulate **mu-opioid receptors** in the enteric nervous system, leading to decreased intestinal motility and increased fluid absorption. **Alvimopan** is a peripherally acting mu-opioid receptor antagonist (**PAMORA**). Its key feature is that it does not cross the blood-brain barrier. Therefore, it selectively blocks the constipating effects of opioids in the gut without reversing the central analgesic (pain-relieving) effects. It is specifically FDA-approved to accelerate gastrointestinal recovery following bowel resection. **2. Analysis of Incorrect Options:** * **A. Loperamide:** This is a peripheral mu-opioid agonist used to treat **diarrhea**. Giving it for OIC would worsen the constipation. * **B. Biperiden:** This is a centrally acting **anticholinergic** drug used primarily to treat Parkinsonism and extrapyramidal side effects of antipsychotics. * **C. Naltrexone:** While this is an opioid antagonist, it is **centrally acting**. If used for OIC, it would cross the blood-brain barrier and immediately precipitate withdrawal symptoms and reverse the patient's pain relief. **3. NEET-PG High-Yield Pearls:** * **Other PAMORAs:** Methylnaltrexone (subcutaneous) and Naloxegol (oral) are also used for OIC, especially in palliative care. * **Mechanism:** PAMORAs are "peripherally restricted," meaning they have high polarity or are substrates for P-glycoprotein, preventing CNS entry. * **Contraindication:** Alvimopan is generally restricted to short-term hospital use due to a potential risk of myocardial infarction with long-term use. * **First-line for OIC:** Usually stimulant laxatives (Senna/Bisacodyl) + stool softeners; PAMORAs are reserved for refractory cases.

Q: Which drug is most likely to be responsible for causing acute pancreatitis?

Didanosine. **Explanation:** **Didanosine (ddI)**, a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in HIV treatment, is classically associated with **dose-dependent acute pancreatitis**. The underlying mechanism involves mitochondrial toxicity due to the inhibition of DNA polymerase-gamma, leading to pancreatic acinar cell injury. It is considered the most common drug-induced cause of pancreatitis among antiretroviral agents. **Analysis of Options:** * **Didanosine (Correct):** High-yield association. Patients often present with elevated serum amylase/lipase and abdominal pain. Risk increases when combined with Stavudine or in patients with alcohol use. * **Ketoconazole:** An antifungal primarily known for causing hepatotoxicity and inhibition of steroid synthesis (leading to gynecomastia), but not typically associated with pancreatitis. * **Saquinavir:** A Protease Inhibitor (PI). While PIs are associated with metabolic side effects like dyslipidemia, insulin resistance, and lipodystrophy (Buffalo hump), they are not the primary cause of drug-induced pancreatitis compared to Didanosine. * **Zidovudine (AZT):** An NRTI whose hallmark toxicities are bone marrow suppression (anemia, neutropenia) and myopathy. It does not typically cause pancreatitis. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Drug-Induced Pancreatitis:** "**FAV PIGS**" – **F**urosemide, **A**zathioprine/Asparaginase, **V**alproic acid, **P**ancratin (Didanosine), **I**I-Estrogens, **G**lucocorticoids, **S**ulfonamides. * **Didanosine** is also associated with peripheral neuropathy. * If a question mentions an HIV patient with pancreatitis, always look for **Didanosine** or **Stavudine** in the options.

Q: Which of the following is TRUE regarding anti-H. pylori therapy EXCEPT?

It is indicated in all patients with peptic ulcer disease.. ### Explanation **1. Why Option A is the Correct Answer (The "Except" Statement):** While *H. pylori* is a major cause of peptic ulcer disease (PUD), it is not the only cause. PUD can also be induced by **NSAIDs, Zollinger-Ellison Syndrome (gastrinoma), or stress**. Anti-*H. pylori* therapy is indicated **only** when the presence of the bacterium is confirmed via diagnostic tests (e.g., Urea Breath Test, Stool Antigen, or Biopsy). Treating all PUD patients empirically without confirmation leads to unnecessary antibiotic use and resistance. **2. Analysis of Other Options:** * **Option B:** *H. pylori* is notorious for developing rapid resistance, especially to **Clarithromycin and Metronidazole**, if used as monotherapy. This is why multi-drug regimens (Triple or Quadruple therapy) are mandatory. * **Option C:** Gastric acid suppression (using PPIs) is crucial because: * It increases the stability and bioavailability of antibiotics (like Amoxicillin and Clarithromycin) which are acid-labile. * It raises the gastric pH to a level where *H. pylori* enters a replicative state, making it more susceptible to antibiotics. * **Option D:** Colloidal Bismuth Subcitrate (CBS) has direct antimicrobial activity and coats the ulcer base. However, it causes **blackening of stools/tongue** and has a metallic taste, leading to poor patient compliance. **3. Clinical Pearls for NEET-PG:** * **Standard Triple Therapy (7-14 days):** PPI + Amoxicillin (1g) + Clarithromycin (500mg) – all twice daily. * **Bismuth Quadruple Therapy:** PPI + Bismuth + Metronidazole + Tetracycline (Preferred in areas with high Clarithromycin resistance). * **Sequential Therapy:** 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole. * **Test of Cure:** Always performed at least **4 weeks** after completion of therapy and **2 weeks** after stopping PPIs.

Q: A small amount of atropine is added to diphenoxylate in order to:

Discourage overdose and abuse of diphenoxylate. **Explanation:** The correct answer is **D. Discourage overdose and abuse of diphenoxylate.** **Medical Concept:** Diphenoxylate is a potent opioid derivative used as an anti-diarrheal agent. Because it is structurally related to pethidine, it has the potential for CNS effects (euphoria) and physical dependence if taken in high doses. To prevent its misuse, it is formulated as **Lomotil**, which contains a sub-therapeutic (sub-maximal) dose of **Atropine** (0.025 mg) added to Diphenoxylate (2.5 mg). If a person attempts to take a large quantity of the drug to achieve a "high," they will simultaneously ingest a toxic amount of atropine. This results in unpleasant anticholinergic side effects such as tachycardia, dry mouth, blurred vision, and urinary retention, thereby acting as a **deterrent to abuse.** **Analysis of Incorrect Options:** * **A & B:** While atropine has mild anti-emetic and anti-spasmodic (anti-motility) properties, the dose added to diphenoxylate is too small to provide significant clinical synergy or therapeutic benefit for vomiting/diarrhea. * **C:** Atropine does not block the side effects of diphenoxylate; in fact, at high doses, it adds its own toxic profile to the clinical picture. **High-Yield Clinical Pearls for NEET-PG:** * **Loperamide vs. Diphenoxylate:** Unlike diphenoxylate, **Loperamide** does not cross the blood-brain barrier significantly (due to P-glycoprotein efflux) and has negligible abuse potential; hence, it does not require atropine addition. * **Treatment of Overdose:** In cases of diphenoxylate overdose, one must manage both opioid toxicity (with **Naloxone** [1]) and potential anticholinergic crisis. * **Contraindication:** Avoid anti-motility agents in infectious diarrhea (e.g., *Salmonella*, *Shigella*) as they may delay the clearance of toxins and lead to toxic megacolon.

Q: Which drug blocks basal as well as stimulated gastric acid secretion without affecting cholinergic, histaminergic, or gastrin receptors?

Omeprazole. ### Explanation The correct answer is **Omeprazole**. **Mechanism of Action:** Omeprazole is a **Proton Pump Inhibitor (PPI)**. It acts by irreversibly inhibiting the **H+/K+ ATPase enzyme** (the "proton pump") located on the apical membrane of gastric parietal cells. Since this pump is the **final common pathway** for acid secretion, PPIs effectively block acid production triggered by *all* stimuli (Food, Gastrin, Histamine, and Acetylcholine) as well as basal secretion. Crucially, PPIs do not bind to or interfere with the receptors themselves; they act downstream at the enzymatic level. **Analysis of Incorrect Options:** * **Loxatidine & Famotidine (Options A & D):** These are **H2-receptor antagonists**. They specifically block the histamine (H2) receptor. While they reduce acid secretion, they do not block the pathways mediated by Gastrin or Acetylcholine, making them less potent than PPIs. * **Pirenzepine (Option B):** This is a selective **M1-anticholinergic** drug. It blocks the cholinergic stimulation of acid secretion but has no effect on histaminergic or gastrin-induced pathways. **High-Yield NEET-PG Pearls:** * **Drug of Choice:** PPIs are the DOC for Peptic Ulcer Disease (PUD), GERD, and Zollinger-Ellison Syndrome. * **Pharmacokinetics:** PPIs are **prodrugs**, administered as enteric-coated formulations to prevent degradation by stomach acid. They are absorbed in the small intestine and activated in the acidic environment of the **canaliculi** of parietal cells. * **Administration:** They should be taken **30–60 minutes before breakfast** for maximum efficacy, as the number of H+/K+ ATPase pumps is highest after a period of fasting.

Q: What is the mechanism of action of ondansetron?

5 HT3 antagonist. **Explanation:** **Ondansetron** is a potent, highly selective **5-HT3 receptor antagonist**. It works by blocking serotonin (5-HT) at 5-HT3 receptors located both peripherally on vagal nerve terminals in the gastrointestinal tract and centrally in the chemoreceptor trigger zone (CTZ) and the nucleus tractus solitarius (NTS). By inhibiting these receptors, it prevents the emetic reflex, making it the first-line drug for **Chemotherapy-Induced Nausea and Vomiting (CINV)** and post-operative nausea. **Analysis of Incorrect Options:** * **A. RANK ligand inhibitor:** This describes **Denosumab**, a monoclonal antibody used in the treatment of osteoporosis and giant cell tumors of the bone. * **B. NMDA antagonist:** This refers to drugs like **Ketamine, Memantine, or Amantadine**, which act on glutamate receptors in the CNS. (Note: The option "MMDA" is likely a typo for NMDA). * **C. NK1 receptor antagonist:** This describes **Aprepitant** and Fosaprepitant. While also used for CINV, they target the neurokinin-1 receptor (substance P) rather than serotonin receptors. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Ondansetron is the DOC for CINV and radiotherapy-induced vomiting. It is **not** effective in motion sickness (where H1 or M1 blockers are used). * **Side Effects:** The most common side effect is **headache** and constipation. * **ECG Changes:** A critical high-yield fact is that ondansetron can cause **QT interval prolongation**, requiring caution in patients with electrolyte imbalances or congenital long QT syndrome. * **Metabolism:** It is primarily metabolized by the liver (CYP2D6).

Q: Which of the following drugs is used for the management of acute variceal bleeding?

Octreotide. **Explanation:** **Octreotide (Correct Answer):** Octreotide is a synthetic long-acting analogue of **Somatostatin**. It is the drug of choice for the emergency management of acute variceal bleeding. It works by causing **splanchnic vasoconstriction**, which reduces portal venous pressure and blood flow to the esophageal varices without the systemic side effects associated with Vasopressin. It also inhibits the release of glucagon, a potent vasodilator of the splanchnic circulation. **Analysis of Incorrect Options:** * **Oxytocin (B):** This is a posterior pituitary hormone used primarily for induction of labor and management of postpartum hemorrhage (PPH) due to its action on uterine smooth muscle. It has no role in portal hypertension. * **Somatotropin (C):** This is another name for **Growth Hormone**. It is used in the treatment of growth hormone deficiency and Turner syndrome. While Somatostatin inhibits Somatotropin, the two have diametrically opposite clinical uses. * **Dexamethasone (D):** A potent glucocorticoid used for its anti-inflammatory and immunosuppressive properties. While used in conditions like cerebral edema or croup, it has no role in acute variceal management. **NEET-PG High-Yield Pearls:** * **Terlipressin** is another preferred agent (a prodrug of Vasopressin) that has been shown to improve survival in acute variceal bleeding. * **Mechanism:** Octreotide reduces portal pressure by inhibiting the release of vasodilatory peptides (like VIP and Glucagon). * **Prophylaxis:** While Octreotide/Terlipressin are for *acute* episodes, **Non-selective Beta-blockers** (e.g., Propranolol, Nadolol) are used for the *primary and secondary prophylaxis* of variceal bleeding. * **Definitive Management:** Endoscopic Variceal Ligation (EVL) is the gold standard procedure performed alongside pharmacotherapy.

Question 1

Which drug is used to manage Cisplatin-induced nausea and vomiting occurring within 24 hours?

Accepted Answer

Ondansetron

Answer

Aprepitant

Answer

Fosaprepitant

Answer

Promethazine

Question 2

A 27-year-old woman occasionally uses calcium carbonate for 'heartburn' symptoms after a large meal. What is the mechanism of action of the prescribed medication for an acid-peptic disorder?

Accepted Answer

Neutralizes gastric acid

Answer

Binds to cysteine

Answer

Inhibits gastrin release

Answer

Irreversible H1-receptor blockade

Question 3

Omeprazole effects are due to:

Accepted Answer

Proton pump inhibitor

Answer

Prostaglandin analogue

Answer

H2 antihistamines

Answer

Ulcer protective mechanism

Question 4

Which of the following medications is used to treat opioid-induced constipation?

Accepted Answer

Alvimopan

Answer

Loperamide

Answer

Biperiden

Answer

Naltrexone

Question 5

Which drug is most likely to be responsible for causing acute pancreatitis?

Accepted Answer

Didanosine

Answer

Ketoconazole

Answer

Saquinavir

Answer

Zidovudine

Question 6

Which of the following is TRUE regarding anti-H. pylori therapy EXCEPT?

Accepted Answer

It is indicated in all patients with peptic ulcer disease.

Answer

Resistance to any single antimicrobial drug develops rapidly.

Answer

Concurrent suppression of gastric acid enhances the efficacy of the regimen.

Answer

Colloidal bismuth directly inhibits H. pylori but has poor patient acceptability.

Question 7

A small amount of atropine is added to diphenoxylate in order to:

Accepted Answer

Discourage overdose and abuse of diphenoxylate

Answer

Suppress associated vomiting of gastroenteritis

Answer

Augment the anti-motility action of diphenoxylate

Answer

Block side effects of diphenoxylate

Question 8

Which drug blocks basal as well as stimulated gastric acid secretion without affecting cholinergic, histaminergic, or gastrin receptors?

Accepted Answer

Omeprazole

Answer

Loxatidine

Answer

Pirenzepine

Answer

Famotidine

Question 9

What is the mechanism of action of ondansetron?

Accepted Answer

5 HT3 antagonist

Answer

RANK ligand inhibitor

Answer

MMDA antagonist

Answer

NK 1 receptor antagonist

Question 10

Which of the following drugs is used for the management of acute variceal bleeding?

Accepted Answer

Octreotide

Answer

Oxytocin

Answer

Somatotropin

Answer

Dexamethasone

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?